{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}],"units":"Participants"}],"description":"Frequency (%) of patients who respond (CR/PR) to crizotinib in combination with either topotecan and cyclophosphamide or vincristine and doxorubicin/dexraroxane stratified by MRD status","groups":[{"description":"Patients receive 165 mg/m\\^2 crizotinib (oral solution) PO BID on days 1-21, 250 mg/m\\^2 cyclophosphamide IV QD on days 1-5, and topotecan hydrochloride IV QD on days 1-5. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)","id":"OG000","title":"Part A Dose Level 1"},{"description":"Patients receive 215 mg/m\\^2 crizotinib (oral solution) PO BID on days 1-21, 250 mg/m\\^2 cyclophosphamide IV QD on days 1-5, and topotecan hydrochloride IV QD on days 1-5. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)","id":"OG001","title":"Part A Dose Level 2"},{"description":"Patients receive 165 mg/m\\^2 crizotinib (oral solution) PO BID as in Part A. Patients also receive 1.5 mg/m\\^2 vincristine sulfate IV on day 1, 450 mg/m\\^2 dexrazoxane hydrochloride IV on day 1, and 45 mg/m\\^2 doxorubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)","id":"OG002","title":"Part B Dose Level 1"},{"description":"Patients receive 215 mg/m\\^2 crizotinib (oral solution) PO BID as in Part A. Patients also receive 1.5 mg/m\\^2 vincristine sulfate IV on day 1, 450 mg/m\\^2 dexrazoxane hydrochloride IV on day 1, and 45 mg/m\\^2 doxorubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)","id":"OG003","title":"Part B Dose Level 2"},{"description":"Patients receive 280 mg/m\\^2 crizotinib (oral solution) PO BID as in Part A. Patients also receive 1.5 mg/m\\^2 vincristine sulfate IV on day 1, 450 mg/m\\^2 dexrazoxane hydrochloride IV on day 1, and 45 mg/m\\^2 doxorubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)","id":"OG004","title":"Part B Dose Level 3"},{"description":"Patients receive 165 mg/m\\^2 crizotinib (capsule formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG005","title":"Part C Dose Level 1"},{"description":"Patients receive 215 mg/m\\^2 crizotinib (capsule formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG006","title":"Part C Dose Level 2"},{"description":"Patients receive 280 mg/m\\^2 crizotinib (capsule formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG007","title":"Part C Dose Level 3"},{"description":"Patients receive 165 mg/m\\^2 crizotinib (microsphere formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG008","title":"Part D Dose Level 1"},{"description":"Patients receive 215 mg/m\\^2 crizotinib (microsphere formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG009","title":"Part D Dose Level 2"},{"description":"Patients receive 215 mg/m\\^2 crizotinib (microsphere formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG010","title":"Part PK Dose Level 2"}],"populationDescription":"Outcome Measure was specific to ALCL patients. There were zero ALCL patients, therefore, there are no data to report.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"MRD Status and Response to Crizotinib","type":"SECONDARY"}